| Revenue growth | 28% YoY growth driven by formulation and EU sales. |
|---|---|
| Margins | EBITDA margins healthy at 28%, aided by formulation mix. |
| Order book | Firm orders in place for Q4, especially for Nor-UDCA. |
| Demand visibility | Strong traction in oncology and non-oncology API segments. |
| Management confidence | Balanced; shift from investment phase to asset monetization and execution. |
Growth
Revenue grew 28% YoY to ₹411cr; EBITDA rose 41% to ₹115cr with 28% margins.
Outlook
Targeting 150cr+ annual licensing income; Albumin commercialization expected in India by FY28.
Risks
High debt levels and pending USFDA clearance for the Jadcherla facility remain key overhangs.
Earnings Call filed with NSE, NSE: SHILPAMED. Summary written with AI assistance from the document.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹1,013.45
- Market cap
- ₹19,821 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 66.7×Sector 50.4×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 11.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Share Pledge
The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.
Shilpa Medicare Other Announcement
Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.
Shilpa Medicare Business Update
Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.
Shilpa Medicare Regulatory Approval
Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.
Shilpa Medicare Annual General Meeting
Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.
Shilpa Medicare Insolvency Petition
NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.
- Value
- ₹2.18 Cr